Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion type Assertion NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_head.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion evidence source_evidence_literature NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion SIO_000772 22210719 NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion wasDerivedFrom befree-2016 NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.
- NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion wasGeneratedBy ECO_0000203 NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.